A new study published in the journal of BMC Gastroenterology showed that dementia risk was higher in patients with metabolic ...

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) ...

DelveInsight's analysis forecasts liver fibrosis market growth due to the introduction of emerging therapies, expecting an increase in market ...

A new blood test can predict the development of metabolic dysfunction-associated steatotic liver disease (MASLD) up to 16 ...

A pioneering research study published today in Cell Metabolism details how the hormone FGF21 (fibroblast growth factor 21) can reverse the effects of fatty liver disease in mice. The hormone works ...

Women who experience menopause before the age of 50 - and especially before the age of 45 - are more likely to develop fatty liver disease and its related metabolic risk factors within one year after ...

Pregnant women with metabolic dysfunction-associated steatotic liver disease (MASLD) face a more than threefold increased risk of preterm birth, according to a new population-based study conducted by ...

Semaglutide and similar GLP-1 drugs are poised to become frontline treatments for a severe form of liver disease.

Aroosha Sarrafi tells Health her story of getting diagnosed with metabolic dysfunction-associated steatohepatitis (MASH), a ...

Using semaglutide injections, scientists were able to reverse life-threatening cases of liver disease in a new clinical trial ...

Women who experience menopause before the age of 50—and especially before the age of 45—are more likely to develop fatty liver disease and its related metabolic risk factors within one year after ...